Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow's milk allergy development in mice

Publication date

2023-01-06

Authors

LIU, MENGSHANISNI 000000051255223X
Thijssen, SuzanISNI 000000049295832X
Hennink, Wim EISNI 0000000390382745
Garssen, JohanORCID 0000-0002-8678-9182ISNI 0000000034097251
van Nostrum, ReneISNI 0000000396379707
Willemsen, LinetteORCID 0000-0001-9882-5331ISNI 0000000391133134

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

Cow's milk allergy is a common food allergy among infants. Improved hygiene conditions and loss of microbial diversity are associated with increased risk of allergy development. The intestinal immune system is essential for oral tolerance induction. In this respect, bacterial CpG DNA is known to drive Th1 and regulatory T-cell (Treg) development via Toll-Like-Receptor 9 (TLR-9) signaling, skewing away from the allergic Th2 phenotype. We aimed to induce allergen specific tolerance via oral delivery of poly (lactic-co-glycolic acid) nanoparticles (NP) co-encapsulated with a selected β-lactoglobulin derived peptide (BLG-Pep) and TLR-9 ligand CpG oligodeoxynucleotide (CpG). In vivo, 3-4-week-old female C3H/HeOuJ mice housed in individually ventilated cages received 6-consecutive-daily gavages of either PBS, whey, BLG-Pep/NP, CpG/NP, a mixture of BLG-Pep/NP plus CpG/NP or co-encapsulated BLG-Pep+CpG/NP, before 5-weekly oral sensitizations with whey plus cholera toxin (CT) or only CT (sham) and were challenged with whey 5 days after the last sensitization. The co-encapsulated BLG-Pep+CpG/NP pretreatment, but not BLG-Pep/NP, CpG/NP or the mixture of BLG-Pep/NP plus CpG/NP, prevented the whey-induced allergic skin reactivity and prevented rise in serum BLG-specific IgE compared to whey-sensitized mice. Importantly, co-encapsulated BLG-Pep+CpG/NP pretreatment reduced dendritic cell (DC) activation and lowered the frequencies of PD-L1+ DC in the mesenteric lymph nodes compared to whey-sensitized mice. By contrast, co-encapsulated BLG-Pep+CpG/NP pretreatment increased the frequency of splenic PD-L1+ DC compared to the BLG-Pep/NP plus CpG/NP recipients, in association with lower Th2 development and increased Treg/Th2 and Th1/Th2 ratios in the spleen. Oral administration of PLGA NP co-encapsulated with BLG-Pep and CpG prevented rise in serum BLG-specific IgE and symptom development while lowering splenic Th2 cell frequency in these mice which were kept under strict hygienic conditions.

Keywords

CpG oligodeoxynucleotides, cow’s milk allergy, individual ventilated cages, oral pretreatment, poly (lactic-co-glycolic acid) nanoparticles, toll-like-receptor 9, whey protein, β-lactoglobulin, Immunology and Allergy, Immunology, SDG 3 - Good Health and Well-being

Citation

Liu, M, Thijssen, S, Hennink, W E, Garssen, J, van Nostrum, C F & Willemsen, L E M 2023, 'Oral pretreatment with β-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow's milk allergy development in mice', Frontiers in Immunology, vol. 13, 1053107. https://doi.org/10.3389/fimmu.2022.1053107